tuneTypical Dose
600 to 1200 mg/day in the direct DCI-alone PCOS literature
Supplement
D-Chiro-Inositol
D-chiro-inositol
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Ovulatory and metabolic changes were assessed over several weeks in the main trials.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
D-chiro-inositol has its clearest use in PCOS-related insulin and ovulatory support, but the evidence is smaller and less secure than generic inositol marketing often implies.
D-chiro-inositol is usually discussed inside the broader inositol family, especially for polycystic ovary syndrome. The direct human evidence supports possible improvements in ovulation, insulin-related measures, and some androgen or cardiometabolic markers in women with PCOS. The limitation is that the evidence base is still relatively small, and broader fertility or glucose claims often overstate what DCI alone has actually proven.
D-chiro-inositol functions in insulin-related second-messenger signaling and may influence glycogen synthesis and downstream metabolic responses. In practice, the relevant clinical evidence is in PCOS rather than in general-population glucose support.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Possible improvement in ovulation in women with PCOS
- Possible improvement in insulin-related and androgen-related markers in PCOS
Secondary Outcomes
- Weak support for broader fertility or general metabolic claims
Safety
Contraindications and Interactions
Contraindications
- Pregnancy without clinician guidance
Side effects
- Mild GI upset
Interactions
- Glucose-lowering therapy
Avoid if
- You are using it for generic fertility claims outside PCOS
- You are treating it as a universal glucose-control supplement
Evidence
Study-level References
dci-SRC-001Randomized controlled trial
Sourceopen_in_newNestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340(17):1314-1320. doi:10.1056/NEJM199905273402103. PMID:10219066.
Population: Obese women with polycystic ovary syndrome.
Dose protocol: 1200 mg/day for 6 to 8 weeks
Key findings: Improved ovulation and selected metabolic and androgen-related outcomes in obese women with PCOS.
Notes: Landmark direct DCI trial.
Paper content
This landmark trial is the main reason D-chiro-inositol still matters as a distinct supplement rather than just as part of mixed inositol products. It showed improvements in ovulation, insulin-related measures, and some androgen and cardiometabolic markers in obese women with PCOS. The study was small and old, but it provides a real direct-human signal for DCI specifically.
dci-SRC-002Randomized controlled trial
Sourceopen_in_newIuorno MJ, Jakubowicz DJ, Baillargeon JP, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87(7):3338-3343. doi:10.1210/jc.2003-031592. PMID:15251831.
Population: Lean women with polycystic ovary syndrome.
Dose protocol: 600 mg/day for 6 weeks
Key findings: Improved insulin-related and some cardiometabolic measures in lean women with PCOS.
Notes: Useful confirmation that the signal is not confined to obese PCOS.
Paper content
This trial extends the DCI signal into lean women with PCOS, which matters because it suggests the compound’s effects are not limited to obesity-associated PCOS. The sample was very small, but it supports low-confidence metabolic and ovulatory framing for DCI specifically.
dci-SRC-003Systematic review and meta-analysis
Sourceopen_in_newFitz V, et al. Inositol for polycystic ovary syndrome. A systematic review and meta-analysis to inform the 2023 update of the International Evidence-based PCOS Guidelines. J Clin Endocrinol Metab. 2024;109(6):1630-1655. doi:10.1210/clinem/dgad762. PMID:38163998.
Population: Women with polycystic ovary syndrome
Dose protocol: Guideline-linked inositol review across 30 PCOS trials
Key findings: Inositols may improve some metabolic measures and potentially ovulation, but the evidence remains limited and uncertain.
Notes: Important modern confidence-setting source.
Paper content
Guideline-linked review found that inositol may improve some metabolic outcomes and possibly ovulation in PCOS, but the overall evidence base remains limited, uncertain, and not clearly superior to standard care. Myo-inositol generally caused fewer gastrointestinal adverse effects than metformin.
dci-SRC-004Umbrella review of meta-analyses from randomized controlled trials.
Sourceopen_in_newDuan M, Yang M, Li C, Wu X, Yin X, Zhu H. Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials. Front Endocrinol (Lausanne). 2026. doi:10.3389/fendo.2026.1741509. PMID:41757236.
Population: Women with polycystic ovary syndrome across 13 included meta-analyses.
Dose protocol: Umbrella review of 13 meta-analyses covering inositol (myo-inositol, DCI, and combination) in PCOS
Key findings: Inositol improved hormonal markers, insulin resistance, and reproductive outcomes (live birth RR 2.29, ovulation approximately 2.75x controls). Myo-inositol outperformed DCI monotherapy for most endpoints.
Notes: Most comprehensive pooled evidence to date. Contextualizes DCI as less effective than myo-inositol alone for most outcomes.
Paper content
This umbrella review synthesized 13 meta-analyses of RCTs evaluating inositol supplementation in women with PCOS. The analysis found that inositol significantly improved hormonal markers (reduced LH and testosterone, increased SHBG), metabolic markers (improved insulin resistance and triglycerides), and reproductive outcomes (live birth rate RR 2.29, ovulation rate approximately 2.75 times controls). Notably, myo-inositol and combination formulations outperformed D-chiro-inositol monotherapy for most outcomes. This is the most comprehensive pooled evidence summary for inositol in PCOS to date and provides useful context for understanding where DCI fits within the broader inositol landscape.